STAT

NOVEMBER 4, 2023

Today STAT turns 8.

Documentation 335

Documentation 335

STAT

JUNE 27, 2023

Dear Readers, Today is an important day in the history of STAT: We have refreshed the look of our homepage and adjusted the teal color that has been synonymous with STAT since we launched nearly eight years ago. Read the rest…

240

240

STAT

FEBRUARY 10, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

247

247

STAT

MARCH 6, 2023

Dear Readers, Let me call your attention to an important new series at STAT: “The Obesity Revolution.” ” Over the coming days and months, we’ll examine a class of obesity drugs that is transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years.

195

195

STAT

MARCH 14, 2023

After months of vigorous deliberations, I’m thrilled to announce our 2023 STATUS List — the definitive roster of leaders in health, medicine, and the life sciences whose work over the past year has advanced those fields. There were, of course, many contenders to choose from.

214

214

STAT

DECEMBER 29, 2022

Dear Reader, From STAT’s first investigations in June 2021 revealing why the FDA gave the go-ahead for a marginally effective Alzheimer’s drug manufactured by Biogen, we have relentlessly stayed on the story.

Drug Development 204

Drug Development 204

STAT

JANUARY 6, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

259

259

STAT

FEBRUARY 17, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay. “ Dental care is in crisis.

Biosimilars 222

Biosimilars 222

pharmaphorum

OCTOBER 13, 2021

The role of the Managing Editor is to act as the editorial figurehead for, and public face of, pharmaphorum and its associated publications, cultivating and maintaining relationships with key editorial and commercial stakeholders. The post Managing Editor appeared first on. Coordinate and lead weekly editorial meetings.

Communication 52

Communication 52

STAT

DECEMBER 23, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

243

243

STAT

DECEMBER 9, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

248

248

STAT

JANUARY 13, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ Pumping milk at JPM was a nightmare.

229

229

STAT

DECEMBER 2, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

246

246

pharmaphorum

OCTOBER 11, 2023

From the editor-in-chief: On Eversana’s acquisition of Healthware Group Mike.Hammerton Wed, 11/10/2023 - 08:42 Bookmark this

59

59

STAT

DECEMBER 16, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ U.S.

Medical Schools 227

Medical Schools 227

pharmaphorum

OCTOBER 13, 2021

8+ years proven work experience as a managing editor, ideally web content. The post Editor (Deep Dive) appeared first on. Qualifications and Experience. BSc/BA in journalism or relevant field. 5+ years working within pharmaceutical industry or healthcare environment.

People Management 52

People Management Communication 52

STAT

APRIL 25, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Each year, STAT chooses a new class of Wunderkinds, showcasing stars of science and medicine who are in the midst of launching their careers.

223

223

pharmaphorum

OCTOBER 13, 2021

The web editor is responsible for driving the editorial strategy and content plan (excluding the news channel) for pharmaphorum.com through engaging with the editorial team / freelancers / external partners to develop and execute high quality content for the website and its associated publications. The post Web Editor appeared first on.

Communication 40

Communication 40

STAT

APRIL 23, 2024

“The findings stand for themselves as yet another demonstration that these mergers really are causing price increases,” said Katherine Gudiksen, a study author and executive editor of the Source on Healthcare Price and Competition at the University of California College of Law, San Francisco.

Hospitals 335

Hospitals 335

STAT

NOVEMBER 18, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay.

228

228

STAT

OCTOBER 31, 2023

Editor’s note: This essay contains spoilers for the Netflix show “The Fall of the House of Usher.” ” “W atch “ The Fall of the House of Usher” on Netflix when you can. F**cking Great! Totally based on the Sacklers—Fictional obviously but so damn good!”

362

362

STAT

MARCH 14, 2024

Editor’s note: A livestream of this event will be embedded below at 1 p.m. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?

Biosimilars 225

Biosimilars 225

STAT

DECEMBER 18, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients. Read the rest…

243

243

STAT

SEPTEMBER 7, 2023

Longtime moderators Marjorie Pollack and Maria Jacobs, along with associate editor Leo Liu, received notification from ISID CEO Linda MacKinnon that their consulting agreements with the International Society for Infectious Diseases were being terminated. Read the rest…

353

353

STAT

JANUARY 12, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Relive this year’s J.P. Morgan Healthcare Conference with the STAT reporters who attended. Get a full rundown of the deals, data, and scuttlebutt and come away with the ideas and water-cooler chatter you need for the year ahead.

237

237

STAT

DECEMBER 26, 2023

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves. Here are three CRISPR developments we’re watching in 2024: Continue to STAT+ to read the full story…

321

321

Pharmaceutical Technology

JANUARY 29, 2024

An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.

104

104

pharmaphorum

APRIL 4, 2024

Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.

112

112

STAT

DECEMBER 1, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

223

223

pharmaphorum

JANUARY 11, 2022

Healthware has appointed Jonah Comstock as editor-in-chief to further growth and expansion of the Group’s Media and Community business which aims at fostering the dialogue and the connections among the digital health community helping industry, policymakers, and physicians to embrace the digital transformation of health.

Communication 52

Communication 52

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

226

226

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

222

222

STAT

JANUARY 5, 2024

As a former editor for diabetes publications, I knew that insurance companies regularly switched people from one brand of insulin to another, or from a name brand of insulin to a generic. Last January, I went to fill my son’s ADHD prescription and was handed a bag with an unfamiliar drug name on it. I had a sinking feeling.

Generic Medicine 288

Generic Medicine Diabetes 288

STAT

SEPTEMBER 20, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Enough talk about fairness, safety, and effectiveness. If we want AI systems to possess these attributes in health care, we have to test them with those goals in mind. Read the rest…

228

228

Pharmaceutical Commerce

APRIL 23, 2024

In an interview with Pharma Commerce Associate Editor Nicholas Saraceno, Will Robinson, Commercial Director, LogiPharma, talks themes of this year's event and future plans for the show.

101

101

Pharmaceutical Commerce

APRIL 19, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Environtainer, suggests how to improve visibility and risk management for cold chain shipping.

105

105

STAT

DECEMBER 15, 2023

that have recently given the green light to Casgevy, bringing the first CRISPR medicine to market just over a decade after the technology’s potential as a genome editor was described in academic research.   With the anticipated approval of the medicine, Europe will join regions including the U.S. and the U.K.

350

350